News and Events July 2020: BioAegis Therapeutics Receives Approval to Proceed with Phase 2 Trial of its Gelsolin COVID-19 Treatment Read More » June 2020: BioAegis Therapeutics Completes Over-Subscribed Financing for COVID-19 Trial Read More » June 2020: KYW InDepth Podcast – Why NIH is Studying a NJ Lab’s COVID-19 Treatment? Read More » May, 2020: Study of BioAegis’ Lead Product, Gelsolin, is Key Component of NIAID Strategic Plan for COVID-19 Research Read More » May, 2020: BioAegis ‘Inflammation Regulator’ Highlighted in CNBC Feature Story on COVID-19 Read More » April, 2020: BioAegis Demonstrates Gelsolin Therapy Can Quell the Cytokine Storm and Promote Tissue Repair Read More » « Previous Page1 … Page4 Page5 Page6 Next » March 18-21, 2025: 44th Annual International Symposium on Intensive Care and Emergency Medicine (ISICEM) Learn More » March 27-28, 2025: MedInvest Biotech & Pharma Investor Conference Learn More » Articles: Insights, intelligence and opinions from our experts. A Pioneering Biotech Promises to Revolutionize Medicine with a Human Protein that Boosts the Body’s Immune System BioAegis Therapeutics expects to unlock the healing powers of gelsolin and develop new treatments for disease. Host-directed Therapeutics for the Next Pandemic: What They Are and Why We'll Need Them by Dr. Lester Kobzik, Chief Scientific Advisor and Professor (emeritus) of Pathology at The Harvard Medical School Sepsis: The Hydra Within Us As Wallstreet Funding for Sepsis Research has Evaporated US Government Funding Picks Up the Slackby Steven Cordovano, Co-founder, VP Business Development Vaccines Alone Are Not The Answer The US is overlooking Covid’s main culprit — the threat that vaccines do not address.by Susan L. Levinson, PhD., Co-founder and CEO
July 2020: BioAegis Therapeutics Receives Approval to Proceed with Phase 2 Trial of its Gelsolin COVID-19 Treatment Read More »
May, 2020: Study of BioAegis’ Lead Product, Gelsolin, is Key Component of NIAID Strategic Plan for COVID-19 Research Read More »
May, 2020: BioAegis ‘Inflammation Regulator’ Highlighted in CNBC Feature Story on COVID-19 Read More »
April, 2020: BioAegis Demonstrates Gelsolin Therapy Can Quell the Cytokine Storm and Promote Tissue Repair Read More »
March 18-21, 2025: 44th Annual International Symposium on Intensive Care and Emergency Medicine (ISICEM) Learn More »